24 noviembre 2013

Yondelis . Biology of ovarian cancer and trabectedin mechanism of action .

Isabelle Ray-Coquard . Future Oncology, December 2013 .

More than 50% of patients with ovarian cancer have genetic alterations in the homologous repair pathway. Trabectedin appears to induce damage more readily in tumor cells with defects in the homologous repair system. Moreover, trabectedin inhibits monocyte differentiation into tumor-associated macrophages and inhibits the production of inflammatory mediators such as IL-6. In patients with platinum-sensitive, relapsed ovarian cancer, trabectedin plus pegylated liposomal doxorubicin was associated with a trend towards improved overall survival by extending the platinum-free interval. These clinical effects could possibly be attributed to actions of trabectedin on the tumor microenvironment (e.g., a reduction of IL-6). Thus, trabectedin is an agent with mechanisms of action especially appropriate for targeting key processes in the biology of ovarian cancer.

Yondelis en Nature . Mode of Action In Myxoid LipoSarcomas .


S Di Giandomenico, R Frapolli, E Bello, S Uboldi, S A Licandro, S Marchini, L Beltrame, S Brich, V Mauro, E Tamborini, S Pilotti, P G Casali, F Grosso, R Sanfilippo, A Gronchi, R Mantovani, R Gatta, C M Galmarini, J M F Sousa-Faro and M D'Incalci .

...

EEUU:Bebidas azucaradas aumentan el riesgo de cáncer endometrial en mujeres .

En concreto, las mujeres posmenopáusicas que informaron de un mayor consumo de bebidas azucaradas tenían un riesgo del 78 por ciento de padecer carcinoma estrógeno-dependiente, el cáncer de endometrio más común. Esta asociación se encuentra de forma dependiente de la dosis: cuanto más bebidas azucaradas se toman, mayor es el riesgo de desarrollar un carcinoma de este tipo.

...

Bayer's EYLEA Approved in Japan for Macular Endema Treatment . Post by Celtia .

(Reuters) - Bayer HealthCare has received approval from Japan's Ministry of Health to treat macular edema secondary to central retinal vein occlusion (CRVO) with its Eylea eye medication, the company said on Friday.

"The additional approval of Eylea in Japan for the treatment of macular edema secondary to CRVO is great news for patients in Japan suffering from this potentially sight-threatening eye condition," said Kemal Malik, member of the Bayer HealthCare Executive Committee and head of global development.

...